Adicet Bio, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Adicet Bio, Inc. (ACET) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$24.53 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-12
- Adicet Bio, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$24.53M.
- Adicet Bio, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2019 was -$17.37M.
- Adicet Bio, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2018 was -$7.90M.
- Adicet Bio, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2017 was -$11.48M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$24.53M 10-K · filed 2026-03-12 |
| 2019-12-31 | -$17.37M 10-K · filed 2020-03-12 |
| 2018-12-31 | -$7.90M 10-K · filed 2020-03-12 |
| 2017-12-31 | -$11.48M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |